|
Originally published In Press as doi:10.1074/jbc.M109530200 on January 23, 2002
J. Biol. Chem., Vol. 277, Issue 14, 11896-11903, April 5, 2002
Impairment of Mineralocorticoid Receptor
(MR)-dependent Biological Response by Oxidative Stress and
Aging
CORRELATION WITH POST-TRANSLATIONAL MODIFICATION OF MR AND
DECREASED ADP-RIBOSYLATABLE LEVEL OF ELONGATION FACTOR 2 IN KIDNEY
CELLS*
Graciela
Piwien-Pilipuk ,
Antonio
Ayala§,
Alberto
Machado§, and
Mario D.
Galigniana ¶
From the Departamento de Química
Biológica, Facultad de Ciencias Exactas y Naturales, Universidad
de Buenos Aires, Ciudad Universitaria, 1428 Buenos Aires, Argentina
and the § Departamento de Bioquímica,
Bromatología y Toxicología, Facultad de Farmacia,
Universidad de Sevilla, 41012 Sevilla, Spain
Received for publication, October 2, 2001, and in revised form, December 18, 2001
 |
ABSTRACT |
Acute and chronic treatments of mice with the
glutathione-depleting agent,
L-buthionine-(SR)-sulfoximine (BSO),
impaired the mineralocorticoid receptor (MR)-dependent
biological response by inhibiting aldosterone binding. This
steroid-binding inhibition was fully reversed when reducing agents were
added to kidney cytosol obtained from mice treated for 5 h, but it
was only partially reversed in cytosol obtained from mice treated for
10 days. Although the oligomeric structure of the MR-hsp90
heterocomplex was always unaffected, a decreased amount of MR protein
was evidenced after the long term treatment. Such a deleterious effect
was correlated with a post-translational modification of MR, as
demonstrated by an increased level of receptor carbonylation. In
addition, a failure at the elongation/termination step was also
observed during the receptor translation process in a reticulocyte
lysate system. Thus, a high polyribosomes/monomers ratio and both
increased proteolysis and decreased ADP-ribosylatable concentration of
elongation factor 2 (EF-2) were shown. Importantly, similar
observations were also performed in vivo after depletion of
glutathione. Notwithstanding the EF-2 functional disruption, not all
renal proteins were equally affected as the MR. Interestingly, both
EF-2 and MR expressed in old mice were similarly affected as in
L-buthionine-(SR)-sulfoximine-treated young
mice. We therefore propose that a dramatic depletion of glutathione in
kidney cells mimics the cumulative effect of aging which, at the end,
may lead to a renal mineralocorticoid dysfunction.
 |
INTRODUCTION |
The biological effects of aldosterone
(ALDO)1 are mediated by the
mineralocorticoid receptor (MR), a ligand-dependent
transcription factor that belongs to the steroid receptor class of
nuclear receptors. The transcriptional activation of the MR in
epithelial cells triggers a series of events that are responsible for
the regulation of the internal medium, i.e. Na+
and H2O retention and K+ and H+ elimination.
Steroid receptors exist as nuclear or cytoplasmic heterocomplexes
associated to the 90-kDa heat shock protein (hsp90) chaperone system
(1, 2). Regardless of its subcellular localization, this association
stabilizes the receptor in its hormone binding and transcriptionally
inactive form. It is thought that upon ligand binding, the steroid
receptors undergo a conformational change that leads to the
dissociation of the hsp90-heterocomplex, dephosphorylation, dimerization, translocation into the nucleus (for cytoplasmic receptors), hyperphosphorylation, and binding to specific
hormone-responsive elements. Nonetheless, the actual temporal sequence
of this cascade of events remains unclear. In contradiction to
what was previously thought, it has been shown that the dissociation of
the hsp90-heterocomplex upon steroid binding is not necessarily the
first step in the signaling pathway (3, 4). Consistent with this
observation, it has also been postulated that the receptor-hsp90
complex requires intact cytoskeletal tracks to move efficiently toward
the nucleus (5). For this translocation process, the activity of the
Ser/Thr phosphatases seems to play a key role (3, 6, 7), and cytoplasmic dynein may be the motor protein required to move the complex on the filaments (8, 9).
Interestingly, the MR nuclear translocation is abrogated by oxidative
stress in intact kidney cells (2). Several studies (10-13) performed
in vitro with both cell-free systems and cells in culture
have demonstrated that cysteine groups on the MR play an essential role
in steroid binding. We have recently provided direct evidence (14) that
the MR function is also affected in vivo in a similar manner
as shown in vitro. Thus, inhibition of ALDO binding to renal
MR was observed after administering mice a transition state inhibitor
of -glutamylcysteine synthetase, L-buthionine-(SR)-sulfoximine (BSO). The
consequent GSH deficiency paralleled the inhibition of the
mineralocorticoid biological responses to the same extent after both
short (5 h) and long (5 days) periods of treatment. We demonstrated
that this effect was due to the inhibition of the steroid binding to MR
due to oxidation of essential cysteine groups rather than changes on
the receptor protein concentration. However, we subsequently observed
that the level of expression of renal MR is systematically decreased after GSH depletion for longer times (i.e. 10 days).
Inasmuch as a wide variety of renal disorders involve the
overproduction of reactive oxygen species (15-17), a decreased level
of MR expression may be relevant to understand the regulation of the
critical acid base and electrolyte balance under normal or pathological
circumstances (e.g. oxidative stress, metal intoxications,
aging, etc.).
A profound imbalance between oxidants and antioxidants has been related
to renal disorders, from minimal change nephritic syndrome to
obstructive nephropathy (16, 18). Moreover, patients with end-stage
renal failure on maintenance hemodialysis are chronically exposed to
the oxidative stress generated by reactive oxygen species due to
perdialytic neutrophil activation (19). Increased concentration of
malondialdehyde (MDA) (20), an intermediate product generated by lipid
peroxidation, and decreased levels of GSH (15) were also found in
plasma and erythrocytes of hemodialyzed patients.
Because the MR is not an exported protein, a decreased rate of protein
synthesis and/or an increased protein degradation in renal cells may
explain the observed diminution of MR levels under chronic oxidative
conditions. The proposition that oxygen radical-mediated oxidation is a
marking step in protein turnover is supported by several observations
(reviewed in Refs. 21 and 22 and references therein) so that most of
the studies were mainly focused on protein degradation. In agreement
with this notion, it has been demonstrated recently that the turnover
of oxidized proteins is enhanced in fibroblasts via proteosomal
activity (23). On the other hand, the molecular mechanism for protein
synthesis failure during the onset of oxidative stress has not been
extensively studied and, consequently, is not completely defined.
Because of this fact and also because oxidized MR seems to be more
stable to thermal degradation (although incapable to bind steroid) than
its "reduced" form (10), we decided to analyze the effect of
oxidative stress generated by GSH depletion on the individual steps of
polypeptide synthesis in kidney. By using the GSH-depleting agent BSO
as an experimental model, we aimed to study the expression of renal MR,
and we correlated this process with the elongation phase of protein
synthesis under in vivo and in vitro conditions.
Because the elongation phase only requires a small number of factors as compared with the initiation step, we also focused our analysis on the
MR translation process. In particular, we searched for putative
post-translational modifications of elongation factor 2 (EF-2), the
main protein implicated in the elongation step. Finally, we discuss our
molecular findings from the perspective of an integrated process that
may take place under normal and pathological conditions.
 |
MATERIALS AND METHODS |
Reagents--
[1,2-3H]ALDO (50 Ci/mmol),
[U-adenosine-14C]NAD (850 mCi/mmol),
NaB[3H]4 (63 Ci/mmol),
[35S]methionine (1,000 Ci/mmol),
L-[3,4-3H]valine (55 Ci/mmol), and
125I-conjugated counterantibodies were from PerkinElmer
Life Sciences. Reduced GSH, GSH monoethyl ester (GME),
L-buthionine-(SR)-sulfoximine (BSO), cumene
hydroperoxide (CH), protein A-Sepharose, butylated hydroxyanisole,
-tocopherol, deferoxamine, mannitol, cysteine, sodium ascorbate,
catalase from bovine liver, and diphtheria toxin from
Corynebacterium diphtheriae were from Sigma. RU486 was a kind gift from Roussell-Uclaf (Romainville, France).
Complete-MiniTM protease inhibitor mixture was from Roche
Molecular Biochemicals. DNA encoding for full-length human MR was
generously provided by Dr. R. Evans (24). TNT Quick-coupled
Transcription-Translation kit was from Promega Corp. (Madison, WI).
Rabbit polyclonal antibodies against EF-2 (25) and the MR (26) were
described previously. The mouse monoclonal IgG antibody against hsp90
was purchased from StressGen (Victoria, British Columbia, Canada).
Donkey anti-rabbit and goat anti-mouse IgG-horseradish peroxidase
antibodies were from Pierce. Chemiluminescence reagents were purchased
from Amersham Biosciences.
Depletion of GSH--
BSO was dissolved in ethanol/propylene
glycol/saline solution (3:5:32). Two daily intramuscular injections of
2.5 mmol BSO/kg were given to BALB/c mice (see below) at intervals of
12 h (8:00 and 20:00 h) during the indicated times. In
co-treatments with GME, three doses of 2.0 mmol/kg of the ester were
also injected (8:00, 14:00, and 20:00 h). The
ALDO-dependent sodium retention and potassium elimination
were measured in urine samples collected as described previously
(14, 27).
Steroid Binding Assays--
Thirty-day-old and 18-month-old male
BALB/c mice were adrenalectomized by dorsal approach and maintained
with Purina Diet 1, saline solution supplemented with 50 µg/ml
dexamethasone, and freshwater ad libitum. Two days before
sacrifice, the steroid was omitted from the saline solution, and food
was removed the previous night. Kidneys were excised after extensive
perfusion with ice-cold phosphate saline solution, and renal
cortex-medulla interphases were homogenized in 1 volume of buffer
MOPS/Mo (20 mM MOPS, 5 mM EDTA, 2 mM EGTA, 10% glycerol, 2 mM DTT, 20 mM Na2MO4, at pH 7.5) containing 1 tablet of protease inhibitor mixture per 5 ml of solution. Homogenates
were centrifuged at 67,000 × g for 45 min at 3 °C,
and the supernatant of this centrifugation was referred to as cytosol.
Renal cytosol was incubated for 12 h at 0 °C with 20 nM [3H]ALDO and 1.0 µM RU486 to
mask the slight cross-reaction of ALDO with the glucocorticoid
receptor. A 500-fold excess of radioinert ALDO was used to determine
the nonspecific binding (20% of the total). Bound steroid was
separated from free steroid by adding 1 volume of 2% charcoal, 0.2%
dextran 15-20. ALDO binding to kidney MR was measured in vivo as
described before (14, 28). Briefly, 30-day-old male mice were treated
with vehicle, BSO, or BSO and GME for the indicated periods. An
intraperitoneal injection of 10 µCi of [3H]ALDO and 20 µg of RU486 (±30 µg ALDO) was given. Kidneys were removed after 20 min and homogenized in buffer MOPS/Mo lacking DTT. Free
[3H]ALDO was cleared from cytosol by adsorption with
charcoal/dextran, and the samples were divided into equal fractions.
The specific binding was measured either without further treatment or
after reincubating cytosol with 10 nM
[3H]ALDO (±500-fold ALDO) for 3 h at 0 °C in the
absence or presence of 2 mM DTT. Free tracer was adsorbed
with charcoal, and the radioactivity was measured.
Renal Polyribosomal Profiles--
Polyribosomes and monomeric
ribosomes were analyzed in post-mitochondrial supernatants treated with
deoxycholate (~65% of the total renal RNA) by using a 20-40%
linear sucrose gradient as described previously (25). The RNA profiles
were monitored by measuring the absorbance at 260 nm and then
semi-quantified by planimetry.
Incorporation of [3H]Valine into Total and Nascent
Polypeptide Chains--
The procedure for the determination of total
proteins was similar to the one described previously (25) for liver.
Mice were anesthetized with pentobarbital (50 mg/kg); the abdomen was
opened, and 25 µCi of L-[3,4-3H]valine in
200 µl of saline solution was injected in the renal artery. Tissue
samples were taken at the indicated times and immediately frozen under
liquid nitrogen until homogenization in 3 volumes of 0.3 M
sucrose. Under these experimental conditions, the radioactivity was
detected in kidney within 5-10 s after the injection of radioactive valine and continued at an approximately linear rate for 2.5-3.0 min.
Therefore, we began to obtain tissue samples 20 s after the injection and during a total period of 2 min. Kidney homogenates in 0.3 M sucrose were diluted with 1 volume of a buffer containing 100 mM Tris and 2 mM magnesium acetate and
centrifuged for 15 min at 4,000 × g. Two ml of the
supernatant were mixed with 0.2 ml of 20% sodium deoxycholate,
incubated on ice for 30 min, and then centrifuged at 8,000 × g for 15 min. Proteins in the resultant supernatant were
used to quantify total and nascent chains. To measure radioactivity of
total renal protein, an aliquot of this supernatant was treated with
10% trichloroacetic acid at 90 °C for 1.5 h. Precipitated
proteins were redissolved with protosol, and the radioactivity was
counted. The incorporation of labeled valine into nascent polypeptides
was determined layering 1.5 ml of supernatant on 6 ml of a medium
containing 1 M sucrose, 1 mM magnesium acetate,
and 1 ml of a 100,000 × g supernatant obtained by
1 h of ultracentrifugation of kidney homogenate (1:2) in 50 mM triethanolamine, 5 mM MgCl2, 25 mM KCl and 0.25 M sucrose (pH 7.3). The mixture
was centrifuged at 25,000 × g, and the resultant pellet was resuspended in 1 ml of distilled water. Proteins were precipitated and the radioactivity counted as described above.
Immunoprecipitation of MR--
We followed a standard technique
as described previously (3, 14). Briefly, renal cytosol was incubated
with the rabbit anti-MR immune serum (or non-immune rabbit serum)
prebound to protein A-Sepharose and washed four times with ice-cold
MOPS buffer supplemented with 100 mM NaCl and 0.01%
Nonidet P-40, and MR and hsp90 were identified by Western blot analysis.
In Vitro Transcription and Translation of the MR--
The
procedure was performed using the TNT Quick-coupled
Transcription/Translation kit from Promega Corp. (Madison, WI)
according to the manufacturer's instructions. Recombinant phMR3750 DNA
encoding for full-length human MR (24) inserted into polylinker
EcoRI site of pGEM4 (Promega Biotech) was used as a template
for transcription with T7 polymerase followed by translation in the
presence of [35S]methionine. Proteins were resolved by
SDS-PAGE and autoradiographed. When the incubations were performed in
the presence of oxidants, the reticulocyte lysate was preincubated for
60 min at 25 °C with either 2.0 mM CH and/or 5.0 mM BSO. In the protection assays against oxidants, a
reducing solution was also simultaneously added to the medium at the
following final concentrations: 20 µM butylated hydroxyanisole, 200 µM -tocopherol, 5 mM
GSH, 5 mM cysteine, 2 mM DTT, 1 mM
sodium ascorbate, 20 mM mannitol, 3 mM
deferoxamine, and 0.5 mg/ml catalase.
ADP-ribosylation of EF-2--
ADP-ribosylation was performed by
a modification of the method used by Galicka et al. (29).
Renal EF-2 was immunoprecipitated from renal cytosol with the rabbit
polyclonal antibody raised against EF-2 precoupled to protein
A-Sepharose. The immune pellet was washed twice with MOPS buffer
containing 100 mM NaCl and 0.01% Nonidet P-40 and twice
with 20 mM Tris buffer at pH 7.4. The pellets were
incubated for 1 h at 37 °C with 50 µl of a solution
containing 20 mM Tris, 10 mM DTT, 10 µM [14C]NAD, and 5 µg of diphtheria
toxin. The pellets were washed four times with 1 ml of 20 mM Tris buffer, and the radioactivity incorporated to the
immunopurified EF-2 was counted.
Purification of EF-2--
EF-2 was isolated from the
ribosome-free extract of rabbit reticulocyte lysate as described by
Ryazanov and Davydova (30). The purity of the final preparation was
verified by SDS-PAGE followed by Coomassie Blue G-250 staining and
parallel Western blotting with anti-EF-2 antibody. The rate of
incorporation of [35S]Met to hMR in rabbit reticulocyte
lysate system supplemented with pure EF-2 was measured after alkaline
hydrolysis followed by trichloroacetic acid precipitation as described
previously (31).
Miscellaneous--
Renal GSH concentration was quantified by an
enzymatic assay as described previously (14). Carbonyl content in
either renal microsomes or immunopurified proteins was measured by
reduction with tritiated sodium borohydride according to Lenz et
al. (32). MDA was measured with the thiobarbituric standard method
described by Estebauer and Cheeseman (33). Statistical tests were
carried out by analysis of variance followed by Bonferroni analysis.
 |
RESULTS |
Effect of GSH Depletion on the Mineralocorticoid
Response--
Table I shows that the
renal concentration of GSH was dramatically decreased when mice were
treated with the -glutamylcysteine synthetase inhibitor, BSO. Such
an efficient depletion was achieved as soon as 5 h after a single
injection of BSO. On the other hand, a co-treatment with the
cell-permeable ester GME fully prevented the deleterious effect of BSO
by preserving (and even increasing) the intracellular levels of GSH. In
agreement with the onset of an oxidative intracellular milieu, an
increased concentration of both MDA, a product generated by the break
down of hydroperoxides, and protein carbonyls were also measured after
acute (5 h) and prolonged (3 and 10 days) treatment. On the other hand,
the levels of these two markers of oxidation were indistinguishable
from untreated controls when mice were co-treated with BSO and
GME.
View this table:
[in this window]
[in a new window]
|
Table I
Oxidative stress abrogates the mineralocorticoid biological effect
Adrenalectomized 30-day-old or 18-month-old mice were treated with BSO
or BSO and GME for the indicated times. Controls were treated with
vehicle only. The mineralocorticoid effect (Na+/K+
ratio) was measured in vivo after injecting a saturating
dose of ALDO as described under "Materials and Methods." Contents
of GSH in renal cytosol and MDA and CO were also quantified in
microsomal fractions. Results are the mean ± S.E.
(n = 6).
|
|
To evaluate the in vivo mineralocorticoid effect, a
saturating dose (28) of 2 µg of ALDO per 100 g of body weight
was injected, and the anti-natriuretic and kaliuretic effects were
measured. ALDO decreased the Na+/K+ urinary
ratio by 80% in control adrenalectomized mice. However, the biological
response to ALDO was attenuated after 5 h of BSO injection, so a
2.5-fold higher Na+/K+ ratio was measured. This
effect was more significant for longer periods of treatment (3 and 10 days). Taken together, these results clearly confirm (14) that the
depletion of renal GSH impairs the mineralocorticoid biological
response. Interestingly, the data shown in Table I also suggest a
similar effect of aging on the mineralocorticoid response. Thus,
18-month-old animals also exhibit high levels of protein carbonyls and
MDA, as well as a decreased biological response to ALDO as compared
with 30-day-old animals.
In Vivo [3H]ALDO Binding Assay--
To evaluate the
MR binding capacity in vivo, control and BSO-treated mice
were injected with [3H]ALDO, and kidneys were excised
after 20 min, a time when renal radioactivity reaches a maximum level
in kidney (28). Renal cytosol was obtained in MOPS/Mo buffer without
DTT; free tracer was cleared by adsorption with charcoal/dextran, and
the samples were divided into equal fractions. The specific binding
(Fig. 1) was measured either without
further treatment or after a reincubation of cytosols with
[3H]ALDO in the absence or presence of 2 mM
DTT. As expected, the treatment with BSO decreased the steroid binding
capacity of MR under in vivo conditions, whereas this
inhibition was fully prevented by co-treatment with GME. When
radiolabeled cytosols were reincubated in vitro with
[3H]ALDO, the specific binding remained unchanged
(gray bars), indicating that the in vivo ALDO
labeling had saturated the MR binding capacity. Consistent with the
notion that an oxidative milieu inhibits the steroid binding capacity
of MR by oxidation of essential cysteine groups, reincubation of these
cytosols in the presence of DTT recovered the specific binding of
cytosolic MR obtained from BSO-treated mice (black bars).
Importantly, such recovering was total in mice treated for 5 h,
but it was only partial in cytosols obtained from mice treated with BSO
for 3 and 10 days. Thus, ~20 and 35% of the MR steroid binding
capacity was not recovered, respectively. Again, old mice exhibited
similar properties as those shown by long term BSO-treated young
mice.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 1.
In vivo ALDO binding to kidney
MR. Thirty-day-old male mice were treated with vehicle
(control), BSO, or BSO and GME for the times indicated
below the graphs. Then an intraperitoneal injection of 10 µCi of [3H]ALDO and 20 µg of RU486 (±30 µg ALDO)
was given. Kidneys were removed after 20 min and homogenized in a
buffer lacking DTT. Free [3H]ALDO was cleared by
adsorption with charcoal/dextran, and the samples were divided into
equal fractions. The specific binding was measured either without
further treatment (white bars) or after a reincubation of
the cytosol for 3 h at 0 °C with 10 nM
[3H]ALDO (±500-fold ALDO) in the absence (gray
bars) or presence (black bars) of 2 mM DTT.
The ALDO binding capacity measured in vivo in 18-month-old
mice is also shown (old mice). Results represent the
means ± S.E. of four animals per group. Different from controls
at *, p < 0.001; **, p < 0.005; and
***, p < 0.010.
|
|
Association of MR with hsp90--
Because the association of hsp90
with MR is an absolute requirement to bind steroid, we analyzed
the co-immunopurification of hsp90 with renal MR after treatment with
BSO. The bar graph in Fig. 2
depicts the ALDO binding capacity measured in vitro in
cytosols obtained from control and treated mice, because these experimental results are similar to those shown in Fig. 1 under in vivo conditions. Moreover, a constant hsp90/MR optical
density ratio (0.19 ± 0.02) was obtained for all the Western
blots shown at the top of Fig. 2 after a densitometric
scanning. These co-immunoprecipitation assays demonstrate that
oxidative stress does not decrease the MR binding capacity by
disrupting the association of MR with the chaperone complex. However,
the amount of MR (and hence, hsp90) recovered in the heterocomplex
after 10 days of treatment with BSO (condition 5) was one-third lower
than the amount of MR protein recovered from either control cytosol
(condition 2), cytosols from BSO-treated mice (conditions 3 and 4), or
GME- and BSO-treated mice (condition 6). These results demonstrate that
the decreased steroid binding capacity of MR measured in renal tissue
was due to a lower concentration of MR rather than an oxidative
disruption of the MR-hsp90 interaction. Western blot analysis of total
cytosol resolved by SDS-PAGE (shown below the bar
graph) evidenced that the cytosolic hsp90 concentration was
greatly increased due to the onset of oxidative stress, and such
induction was fully prevented by co-treatment with GME (condition 6). A
Western blot for -tubulin was also performed in the same samples,
and no change was evidenced for this essential cytoskeletal
protein.

View larger version (54K):
[in this window]
[in a new window]
|
Fig. 2.
Co-immunoprecipitation of hsp90 with the
MR. Mice were treated with BSO alone or co-treated with BSO and
GME for the indicated times. Kidney cytosol was then obtained, and the
MR was immunoprecipitated. A Western blot for MR and
co-immunoprecipitated hsp90 is shown at the top of the
figure. An aliquot of this cytosol was used to perform a steroid
binding assay (bar graph) and depicted as the means ± S.E. (n = 4). A second aliquot of cytosol was
Western-blotted for hsp90 and -tubulin (shown on the
bottom of the graphic). Conditions are as follows.
1, Non-immune pellet was obtained by incubation of control
cytosol with a preimmune rabbit IgG antibody. 2, Control
cytosol was from untreated mice. Cytosol from BSO-treated mice for
5 h (3), 3 days (4), and 10 days
(5). 6, Cytosol was from mice co-treated with BSO
and GME for 10 days. 7, Cytosol was from 18-month-old mice.
As compared with condition 2, differences of specific binding are
significant at p < 0.001 for conditions 3-5, and
p < 0.005 for condition 7.
|
|
Importantly, Fig. 2 also demonstrates that all the features observed in
chronically stressed young mice were also present in untreated old mice
(compare conditions 5 and 7), reinforcing the similarities pointed out
before between oxidative stress and natural aging.
In Vitro Transcription and Translation of Human MR--
The
decreased concentration of MR obtained by chronic oxidative stress can
be due to receptor degradation or a less efficient receptor synthesis.
There are evidences in favor of both possibilities. Thus, it is known
that radically mediated damaged proteins are often functionally
inactive, and their unfolding was associated with enhanced
susceptibility to proteases (22). However, we have reported previously
(10) that the oxidized MR protein, although incapable to bind steroid,
seems to be quite stable as compared with its reduced
counterpart. Moreover, recent evidence supports the notion that protein
synthesis may decline under oxidative conditions by changes in the
polypeptide elongation rate (34, 35). Therefore, we focused our study
on the various steps of protein synthesis under oxidative conditions.
We first analyzed the expression of a DNA template encoding for human
MR by using the rabbit reticulocyte in vitro
transcription/translation system. A main 35S-labeled
product can be seen as a 110-kDa band in Fig.
3A, as this molecular weight
is compatible with the size of human MR (24). Importantly, this 110-kDa
band was also revealed by Western blot with the anti-MR antibody (data
not shown). Preincubation of reticulocyte lysate with BSO failed in
affecting the MR translation in a significant form (Fig. 3A,
compare lane 2 versus 1). In part, this failure may be due to the mechanism of action of the transition state enzymatic inhibitor. In effect, BSO is present in a
post-mitochondrial medium that lacks an efficient source of peroxide
radical products generated during, for example, an active oxidative
metabolism. Then the simple inhibition of the GSH synthesis under these
in vitro conditions may not be sufficient to affect
significantly the translation machinery. That this may be the case is
supported by the significant inhibition of MR expression achieved with
cumene hydroperoxide (CH) (Fig. 3A, lane 3), a
known generator of reactive oxygen intermediates (25, 36, 37), and also
because of the potentiation obtained when both agents, BSO and CH, were
used together (Fig. 3A, lane 5). As expected for
a radically mediated effect, the CH-dependent inhibition of
MR synthesis was abolished when the lysate was preincubated with CH in
the presence of a reducing mixture (Fig. 3A, lane
4) containing 20 µM butylated hydroxyanisole, 200 µM -tocopherol, 5 mM GSH, 5 mM
cysteine, 2 mM DTT, 1 mM sodium ascorbate, 20 mM mannitol, 3 mM deferoxamine, and 0.5 mg/ml
catalase. Inasmuch as the synthesis of MR was performed in
vitro, two steps are then required to complete the process, template transcription followed by translation. It could be possible that a decreased production of MR may be due to a failure in the former
process rather than in the translation step. Therefore, we performed
direct studies on the initiation and completion steps of the
polypeptide synthesis by analyzing the polyribosomal profiles in
reticulocyte lysates under normal and oxidative conditions. A
representative linear sucrose gradient is depicted in Fig.
3B. It shows that an increased ribosomal state of
aggregation was obtained under oxidative conditions. Thus, the
polysomes/monomers ratio was 4-fold higher in treated lysates than in
control samples (66 versus 16, respectively). The higher
polysomes/monomers ratio observed in CH-treated lysate is the
consequence of both a 2-fold increased amount of polysomes and also a
50% reduction of the single 80 S ribosome forms. It is known that the
cycling between single ribosomal subunits (forms not involved in
translation) and polyribosomes is very rapid (38, 39), and those
ribosomes released at chain termination may either become monomeric
ribosomes or may be converted into native subunits (31, 40) unless the initiation is suppressed, in which case accumulation of single ribosomes occurs (41-43). Therefore, the results shown in Fig. 3B agree with the notion that the elongation/termination
step should be more affected by oxidative stress than the initiation step during the translation process.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 3.
In vitro translation of human MR.
A, electrophoretic analysis of the translated product. The
transcription/translation system was pretreated for 30 min at 25 °C
as follows: lane 1, untreated control; lane
2, 5 mM BSO; lane 3, 2 mM CH;
lane 4, 2 mM CH and the reducing mixture
described under "Materials and Methods"; lane 5, 5 mM BSO and 2 mM CH. The translation reaction
was performed in the presence of [35S]methionine.
Proteins were resolved by SDS-PAGEand autoradiographed. The
arrow shows the band of MR when a Western blot revealed it.
B, sucrose gradient of rabbit reticulocyte ribosomes.
Polyribosomal profiles from normal lysate (solid line) and
CH-treated lysate (dotted line) were determined as described
under "Materials and Methods." The arrow shows the 80 S
monomers. C, ADP-ribosylatable concentration of EF-2. EF-2
was immunoprecipitated from reticulocyte lysate pretreated in the same
conditions as described for A (lanes 1-5). A
Western blot of this immunoprecipitation is shown at the top
of the bar graph for each condition. The active
concentration of EF-2 was measured by using a standard reaction with
[14C]NAD and diphtheria toxin. The bar graph
represents the means ± S.E. (n = 3) for the
percentage of active EF-2 with respect to the untreated lysate
(condition 1) standardized as 100% (11.3 ± 1.9 pmol/mg). Conditions 3 and 5 are significantly
different from condition 1 at p < 0.001.
|
|
The main protein implicated in the elongation step is the EF-2.
Therefore, we analyzed the EF-2 level by Western blotting aliquots of
reticulocyte lysate incubated with BSO and CH, and no differences were
observed for the total concentration of EF-2 in any condition (data not
shown). It is known that ADP-ribosylation of a peculiar diphthamide
residue present on EF-2 abolishes its ability to translocate the
peptidyl-tRNA from the A-site to the P-site on the ribosome (44).
Furthermore, ADP-ribosylation of EF-2 with diphtheria toxin and NAD
have been used as an indicator of the active EF-2 fraction (25, 29, 34,
45). Therefore, we immunopurified EF-2 from reticulocyte lysate and
determined the amount of active protein. Fig. 3C
demonstrates that the amount of ADP-ribosylatable EF-2 was reduced by
50 and 80% in CH- and CH/BSO-treated samples (conditions 3 and 5, respectively). This reduced level of active EF-2 was not observed when
the incubation was performed in the simultaneous presence of the
reducing mixture. Taken together, the results shown in Fig. 3 suggest
that it is entirely possible that the decreased MR concentration
observed in GSH-depleted mice may lie on the inability of renal cells
to achieve efficiently the completion of the nascent protein, more specifically due to transformation of EF-2.
The Addition of Purified EF-2 Recovers the Transcription of hMR in
Vitro--
Given the number of proteins that are likely to be modified
during oxidative stress, a direct role of EF-2 cannot be ensured from
our previous experiments. Nonetheless, if the damage of EF-2 is one of
the reasons for the observed decrease in hMR levels during the
transcription, the addition of purified EF-2 to the transcription/translation system should correct such deficiency. Therefore, we first purified EF-2 from rabbit reticulocyte lysate and
adjusted the amount to be added to the translation medium by comparison
with the endogenous level of EF-2 present in reticulocyte lysate. The
Western blot shown in Fig. 4A
shows that 0.3 µl of purified EF-2 (referred to as 1×) matches the
concentration of endogenous EF-2 in 5.0 µl of reticulocyte lysate, so
that we used this relative amount of EF-2 as a reference. We then
supplemented the CH-treated reticulocyte lysate employed as a
transcription/translation system with purified EF-2. The hMR
translation products are shown in Fig. 4B. As can be seen,
the inhibitory effect of oxidative stress on the hMR translation was
prevented when purified EF-2 was added to the incubation medium (Fig.
4B, compare lane 3 versus lane
2). On the other hand, the addition of purified EF-2 preincubated with 2 mM CH exhibited no effect on the level of expression
of hMR (Fig. 4B, compare lanes 4 versus lane 1).

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 4.
The addition of purified EF-2 to reticulocyte
lysate prevents the harmful effect of a low redox potential medium on
the translation process. A, relative amount of purified
EF-2. Various amounts (0.3, 0.6, and 1.2 µl) of the final preparation
of purified EF-2 were compared by Western blotting with the endogenous
level of EF-2 present in 5 µl of reticulocyte lysate. The ratio 0.3 µl of pure EF-2 to 5 µl of reticulocyte lysate is referred to as 1 time. B, translation of hMR in reticulocyte lysate system.
The translation reaction was performed as described for Fig.
3B and autoradiographed for the
[35S]Met-labeled hMR. Conditions are as follows:
1, untreated control; 2, lysate treated with 2 mM CH; 3, lysate treated with 2 mM
CH and supplemented with 2 times purified EF-2; 4, lysate
treated as in condition 3 but EF-2 was incubated for 1 h at
25 °C with 2 mM CH. C, rate of synthesis. The
radioactivity associated to the trichloroacetic acid-insoluble product
was measured as a function of the translation time. Conditions are as
follows: untreated control (solid circles), lysate treated
with 2 mM CH (open circles), lysate treated with
CH and supplemented with EF-2 as follows: 1× (open square),
2× (solid squares, solid line), or 2× stored
for 24 h in a buffer containing 2 mM CH (solid
squares, dotted line). Results are the average of two
independent experiments performed by duplicate.
|
|
Fig. 4C depicts the rates of synthesis of hMR measured as
incorporation of [35S]methionine to the acid-insoluble
fraction. The rate of synthesis of 35S-labeled hMR was
greatly decreased under oxidative conditions, whereas the addition of
purified EF-2 to the medium was able to correct the translation process
in a concentration-dependent manner. In contrast, when the
translation mixture was supplemented with the same preparation of EF-2
that had been preinactivated with CH, the correction of the hMR
translation was not observed. The purified EF-2 protein remains stable
under the conditions used for the preincubation with CH (as judged by
SDS-PAGE followed by Coomassie Blue staining), although its
ADP-ribosylation by diphtheria toxin was fully abolished (data not shown).
Taken together, these results clearly indicate that EF-2 may be
responsible for the observed decrease of hMR level during the
translation process under oxidative conditions.
Renal Polyribosomal Profiles--
In view of the previous
observations, we next analyzed the polysome profiles in kidney cytosol
after mice were treated with BSO. Results are shown in Fig.
5. Consistent with the above-described in vitro effect, Fig. 5A shows an increased
ribosomal state of aggregation when oxidative stress was generated
in vivo by treatment with BSO for 3 and 10 days (25 and 82%
larger polyribosome peak, respectively). On the other hand, the
polyribosomal profile for BSO- and GME-co-treated mice was
indistinguishable from that obtained with untreated mice (Fig.
5B). In addition, the polyribosomes/monomers ratio was also
increased in 18-month-old mice (116%), strengthening the notion that
aging is a process where cumulative damage by oxidation affects the
protein synthesis machinery.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 5.
Polyribosomal profiles and polypeptide
completion time in kidney. A sucrose gradient of renal polysomes
was performed after 30-day-old mice were treated under the following
conditions (polysomes/monomers ratios are given in parentheses).
A, untreated controls (solid line) (13); mice
treated with BSO for 3 days (dashed line) (40), or 10 days
(dotted line) (59). B, untreated 30-day-old
controls (solid line) (13), untreated 18-month-old mice
(dashed line) (47); 30-day-old mice co-treated with GME and
BSO for 10 days (dotted line) (12). C,
[3H]valine incorporated into renal Pn and Pt was measured
in 30-day-old mice treated for 10 days with either vehicle (black
circles) or BSO (white circles). The Pn/Pt ratio for
untreated 18-month-old mice is also shown (black squares).
The completion time was calculated from the slope of each function. The
points represent the means ± S.E. of four mice.
|
|
We then measured the polypeptide chain completion time. This parameter
is accepted as a quantitative expression of the rate of peptide chain
elongation and termination (25, 34, 46, 47). The radioactivity
incorporated into both nascent peptides in polyribosomes (Pn) and total
peptides (Pt) was plotted against the time after the injection of
[3H]valine into the renal artery. The value of Pn for
each animal was then divided by the corresponding value of Pt, and the
Pn/Pt ratio was finally plotted against the time (Fig. 5C).
If it is assumed that the radioactive amino acid will meet the
ribosomes in the middle of the translation of a mRNA of average
size (25, 46, 47), so the whole peptide on the ribosome should be
labeled when a full cycle is completed. In turn, those chains that have been terminated and released will be only 50% labeled. After a second
cycle, 1 full unit will increase the pool of released peptides, whereas
the Pn/Pt ratio should have been reduced to 25%. Thus, the time
required to reduce Pn/Pt from 50 to 25% should be representative of
the average completion time (elongation and termination steps). This
time is independent of both the number of ribosomes engaged in the
process and variations in the initiation step and can be calculated
directly from the slope of the function. In our hands, the average
completion time increased from 58 to 98 s in mice treated with BSO
for 10 days. Old mice evidenced a completion time equal to 158 s.
Damage of Renal MR and EF-2--
We then measured the
ADP-ribosylatable content of EF-2 immunopurified from kidney cytosol of
BSO-treated mice. Fig. 6 shows that the
active amount of EF-2 was reduced nearly 50% after 10 days of GSH
depletion (hatched bars). In turn, the protein carbonyl content in the immune pellets was increased 2-fold (black
bars). Both deleterious effects were totally prevented by GME. On
the other hand, the content of carbonyls measured in MR immunopurified from BSO-treated mice (white bars) was increased 40% with
respect to untreated animals. A similar level of MR carbonylation was also measured in 18-month-old mice.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 6.
Oxidative damage of renal MR and EF-2.
A, protein carbonylation and ADP-ribosylation of
immunopurified EF-2. Thirty-day-old mice were treated for 10 days with
BSO or GME and BSO. The carbonyl group content of MR and EF-2 and the
ADP-ribosylatable level were measured in immunopurified samples. The
same parameters were also measured in immune pellets obtained from
untreated 18-month-old mice. Bars represent the means ± S.E. (n = 4) for ADP-ribosylatable EF-2 content
(hatched bars), carbonyl groups in EF-2 (black
bars), and the MR (white bars). Results are presented
as a percentage of the value measured in untreated 30-day-old animals
(23.5 ± 1.8 nmol of MDA/mg protein, and 387 ± 40 nmol and
protein carbonyls group/mg protein). Values are significantly different
at *, p < 0.005, and **, p < 0.010. B, proteolytic fragmentation of renal EF-2. Proteins from
renal cytosol were resolved by SDS-PAGE, and EF-2 was visualized by
Western blotting. Conditions are as follows: 1, cytosol from
30-day-old mice; 2, cytosol from BSO-treated mice for 3 days; 3, cytosol from BSO-treated mice for 10 days;
4, cytosol from mice co-treated with BSO and GME for 10 days; 5, cytosol for untreated 18-month-old mice.
Arrows on the right side show molecular weight
markers. Arrows on the left side show the
full-length EF-2 band and its main degradation products at 39, 51, and
67 kDa.
|
|
In the experiment shown in Fig. 2, we demonstrated that the quaternary
structure of the MR-hsp90 heterocomplex was not affected by oxidative
stress. Those Western blots did not show lower molecular mass
proteolytic fragments of MR. This observation agrees with the results
shown in Fig. 3A and those described previously (10). On the
other hand, Parrado et al. (34) have recently reported that
rat liver EF-2 does undergo fragmentation upon the onset of oxidative
stress induced by CH. As a consequence, we studied the putative
fragmentation of cytosolic EF-2 in mouse kidney after treatment with
BSO. Fig. 6B shows the protein profile obtained with the
anti-EF-2 antibody in renal cytosol. Thirty-day-old untreated mice
exhibited a main band of EF-2 at the expected molecular mass of 100-kDa
(Fig. 6B, lane 1). Besides this band, cytosol
from BSO-treated mice also exhibited a major proteolytic fragment at 39 kDa and two minor bands at 51 and 67 kDa (lanes 2 and
3). The full prevention of the EF-2 fragmentation observed
in cytosol of GME co-treated mice (lane 4) proves that
proteolysis of EF-2 in vivo depends on the onset of
oxidative stress. Thus, old mice also exhibit a fragmentation pattern
of EF-2 similar to that generated by the depletion of GSH in young mice
(lane 5). However, the total amount of full-length EF-2 was
also significantly decreased in old mice, an observation that is
consistent with the significantly slower half-transit time of nascent
polypeptides observed in Fig. 5C for this group of animals.
Diminished EF-2 levels were also found in liver of CH-treated rats
(34). Curiously, despite the lower full-length EF-2 level observed for
old mice, Fig. 6B also shows that the amount of proteolytic
fragments remained unchanged. This observation may be related to the
inhibition of the proteosome activity described in certain old cells
(23), which in turn leads to the cyclic accumulation of damaged and
aggregated proteins.
 |
DISCUSSION |
In this work we demonstrated that oxidative stress impairs the
mineralocorticoid biological response by two different molecular mechanisms. As supported by the experiments described in Table I and
Figs. 1 and 2, one of these inhibitory mechanisms involves the
post-translational modification of the receptor protein by oxidation.
Consistent with the results reported in the literature (10-14), it is
most likely that oxidization of essential cysteine groups is the main
responsibility for such inhibition. In the short time (hours), the
inhibitory effect observed by depletion of GSH can be fully reversed
in vitro by incubating renal cytosol with DTT or can be
totally prevented in vivo by co-administering GME. A second
harmful mechanism able to affect the mineralocorticoid response was
evidenced after several days of GSH depletion, and it affected the
protein translation system at the elongation/termination steps.
Because polyribosomes can be formed in vitro (Fig.
3B) and in vivo (Fig. 5, A and
B), and there was a decreased number rather than
accumulation of monomers, it is unlikely that the initiation step can
be as strongly affected as the completion step (41-43). In agreement
with the notion that the elongation/termination step is affected by the
onset of oxidative stress, the rate of translation in vitro
was restored after addition of purified EF-2 to the incubation medium
(Fig. 4). Moreover, the half-transit rate of nascent polypeptide chains
in renal cells is almost twice as slow in BSO-treated mice as in the
untreated controls. The observed effects on protein synthesis during
the BSO-dependent depletion of renal GSH are similar to
those described in the liver of rats treated with the radical donor
cumene hydroperoxide (25, 34). We emphasize that we were unable to
generate an efficient oxidative stress with BSO in adult rats and older
mice. BSO is a compound that seems to be efficient to induce oxidative
stress only on certain animal models such as guinea pigs, newborn rats,
or young mice (48).
Our results provide clear evidence that the impairment of the
mineralocorticoid biological response is correlated with an increased
content of tissue MDA, a high carbonylation level of MR and EF-2, and a
decreased amount of biologically active EF-2 (as determined by its low
ADP-ribosylatable level). Interestingly, not all proteins are affected
by oxidative stress to an equivalent extent. Thus, the concentration of
hsp90 was greatly increased, whereas renal -tubulin remained
unchanged after the treatment with BSO (Fig. 2). In a previous work
(14), we have also analyzed the activity of several proteins related to
the mechanism of action of MR, such as citrate synthase,
11 -hydroxysteroid dehydrogenase, Na+/H+
antiport, and Na+/K+-ATPase. There were no
dramatic changes in any of these proteins. Moreover, the
Na+/K+-ATPase activity seems to be preserved
due to an increased number of active pumps, so that a decreased
specific activity of the Na+/K+-ATPase pumps
was inferred from these observations. Oxidative stress is intrinsically
associated with a state of increased turnover of biomolecules induced
by elevated rates of reactive oxygen species. However, extensive
studies have recently demonstrated that other proteins also increase
their activity upon oxidative stress in a significant manner, for
example c-Jun NH2-terminal kinase (49), p70-S6 kinase (50),
Akt/PKB (51), glucose-6-phosphate dehydrogenase (52), PDK1 (53), and
SGK (54), among many other examples. Interestingly, the last two
proteins are related to the mineralocorticoid biological response.
Thus, the serum- and glucocorticoid-dependent kinase
(SGK) has been linked to the ALDO-dependent
mechanism of activation of the epithelial sodium channel (55, 56). In
turn, there exists substantial evidence showing that SGK is
regulated by the phosphoinositide-dependent kinase 1, PDK1.
Therefore, it seems that there also exist several regulatory mechanisms
that are simultaneously triggered by oxidative stress, so that such a
compensatory regulation attenuates damaging effects like those evidenced here for the MR-mediated biological response and the translation machinery.
On the other hand, aging is related to a decrease in the stress
response and the loss of a low redox potential milieu (22, 57). It has
been reported recently (25) that oxidative stress induced by
xenobiotics decrease protein synthesis, as this effect is due to a
decreased efficiency in the elongation step during the translation
process. Similar conclusions were reached when aging-related effects
were also compared with free radical damage (34). Because the ALDO
binding capacity of renal MR decreases with aging, and because the
similar pattern evidenced in this work between the harmful effects of
GSH depletion and aging, we may certainly speculate that the cumulative
damage generated along the lifetime by oxidative stress may affect
renal cells (and other tissues as well) in a similar manner as that
described here for mice treated with BSO. Nonetheless, a key conundrum
such as whether or not protein damaging is primary or secondary in
aging still remains to be answered.
It is reasonable to state that the extent of any type of oxidative
stress must be exacerbated by a decreased efficiency in the natural
antioxidant compounds. Investigation of the GSH enzymatic system in
patients with chronic renal failure has revealed that the activities of
GSH peroxidase and GSH reductase as well as the plasma GSH
concentration were significantly reduced (15). Consistent with the
predominant synthesis of GSH peroxidase in the renal tubule, a dramatic
decrease in plasma enzymatic activity was also observed. Depletion of
GSH can also contribute to renal dysfunction because this thiol is not
only an efficient radical scavenger but is also an important detoxicant
for eliminating different electrophilic compounds of exogenous and
endogenous origin via glutathione S-transferase activity.
Therefore, GSH deficiency may contribute to the accumulation of harmful compounds.
In summary, the molecular findings presented in this work contribute to
an emerging picture that shows a decreased renal
MR-dependent biological response as a consequence of the
depletion of the GSH antioxidant system. This failure is linked to both
post-translational modification of the receptor protein and impaired
polypeptide synthesis. These findings may be related to the undesired
kidney dysfunction observed during normal aging and certain
pathological conditions.
 |
ACKNOWLEDGEMENT |
We are indebted to Dr. R. Evans for the kind
provision of recombinant DNA encoding for human MR.
 |
FOOTNOTES |
*
This work was supported by grants from Consejo Nacional de
Investigaciones Científicas y Técnicas de la
República Argentina and Ministerio de Sanidad y Consumo de
España Grant FIS 96-1442.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: 1301 Medical
Science Research Bldg. III, Dept. of Pharmacology, the University of
Michigan Medical School, Ann Arbor, MI 48109. Tel.: 734-764-5414; Fax:
734-763-4450; E-mail: mgali@umich.edu.
Published, JBC Papers in Press, January 23, 2002, DOI 10.1074/jbc.M109530200
 |
ABBREVIATIONS |
The abbreviations used are:
ALDO, aldosterone;
MR, mineralocorticoid receptor;
hsp90, 90-kDa heat shock protein;
BSO, L- buthionine-(SR)-sulfoximine;
CH, cumene
hydroperoxide;
GSH, reduced glutathione;
GME, glutathione monoethyl
ester;
MDA, malondialdehyde;
EF-2, elongation factor 2;
Pt, total
peptides;
Pn, nascent peptides;
DTT, dithiothreitol;
MOPS, 4-morpholinepropanesulfonic acid;
SGK, serum- and
glucocorticoid-dependent kinase.
 |
REFERENCES |
| 1.
|
Pratt, W. B.,
and Toft, D. O.
(1997)
Endocr. Rev.
18,
306-360[Abstract/Free Full Text]
|
| 2.
|
Galigniana, M. D.
(2000)
Curr. Top. Steroid Res.
3,
1-22
|
| 3.
|
Galigniana, M. D.
(1998)
Biochem. J.
333,
555-563[Medline]
[Order article via Infotrieve]
|
| 4.
|
Galigniana, M. D.,
Housley, P. R.,
DeFranco, D. B.,
and Pratt, W. B.
(1999)
J. Biol. Chem.
274,
16222-16227[Abstract/Free Full Text]
|
| 5.
|
Galigniana, M. D.,
Housley, P. R.,
Scruggs, J. L.,
Herrington, M. J.,
Welsh, M. J.,
Carter-Su, C.,
and Pratt, W. B.
(1998)
Mol. Endocrinol.
12,
1903-1913[Abstract/Free Full Text]
|
| 6.
|
DeFranco, D. M., Qi, M.,
Borror, K.,
and Brautigan, D. L.
(1991)
Mol. Endocrinol.
5,
1215-1229[Abstract/Free Full Text]
|
| 7.
|
Piwien-Pilipuk, G.,
and Galigniana, M. D.
(1998)
Mol. Cell. Endocrinol.
144,
119-130[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Silverstein, A. M.,
Galigniana, M. D.,
Kanelakis, K. C.,
Radanyi, C.,
Renoir, J. M.,
and Pratt, W. B.
(1999)
J. Biol. Chem.
274,
36980-36986[Abstract/Free Full Text]
|
| 9.
|
Galigniana, M. D.,
Radanyi, C.,
Renoir, J. M.,
Housley, P. R.,
and Pratt, W. B.
(2001)
J. Biol. Chem.
276,
14884-14889[Abstract/Free Full Text]
|
| 10.
|
Galigniana, M. D.
(1996)
Life Sci.
59,
511-521[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Souque, A.,
Fagart, B.,
Coutte, M. E.,
and Rafestin-Oblin, M. E.
(1996)
J. Steroid Biochem. Mol. Biol.
57,
315-321[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Lupo, D.,
Mesnier, G.,
and Auzou, G.
(1998)
Biochemistry
37,
12153-12159[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Galigniana, M. D.,
and Piwien-Pilipuk, G.
(1999)
Biochem. J.
341,
585-592[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Piwien-Pilipuk, G.,
and Galigniana, M. D.
(2000)
Biochim. Biophys. Acta
1495,
263-280[Medline]
[Order article via Infotrieve]
|
| 15.
|
Ceballos-Picot, I.,
Witko-Sarsat, V.,
Merad-Boudia, M.,
Nguyen, A. T.,
Thévenin, M.,
Jaudon, M. C.,
Zingraff, J.,
Verger, C.,
Jungers, P.,
and Descamps-Latscha, B.
(1996)
Free Radic. Biol. Med.
21,
845-853[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Nath, K. A.,
and Salahudeen, A. K.
(1990)
J. Clin. Invest.
86,
1179-1192[Medline]
[Order article via Infotrieve]
|
| 17.
|
Yoshioka, T.,
Bills, T.,
Moore-Jarrett, T.,
Greene, H. L.,
Burr, I. M.,
and Ichikawa, I.
(1990)
Kidney Int.
38,
282-288[Medline]
[Order article via Infotrieve]
|
| 18.
|
Baud, L.,
and Arcaillou, R.
(1986)
Am. J. Physiol.
20,
F765-F776
|
| 19.
|
Himmelfarb, J.,
Ault, K. A.,
Holbrook, D.,
Leeber, D. A.,
and Hakim, R. M.
(1993)
J. Am. Soc. Nephrol.
4,
178-186[Abstract]
|
| 20.
|
Dasgupta, A.,
Hussain, S.,
and Ahmad, S.
(1992)
Nephron
60,
56-59[Medline]
[Order article via Infotrieve]
|
| 21.
|
Stadman, E. R.
(1992)
Science
257,
1220-1224[Abstract/Free Full Text]
|
| 22.
|
Dean, R. T., Fu, S.,
Stocker, R.,
and Davies, M. J.
(1997)
Biochem. J.
324,
1-18[Medline]
[Order article via Infotrieve]
|
| 23.
|
Merker, K.,
Sitte, N.,
and Grune, T.
(2000)
Arch. Biochem. Biophys.
375,
50-54[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Arriza, J. L.,
Weinberger, C.,
Cerelli, G.,
Glaser, T. M.,
Handelin, B. L.,
Housman, D. E.,
and Evans, R. M.
(1987)
Science
237,
268-275[Abstract/Free Full Text]
|
| 25.
|
Ayala, A.,
Parrado, J.,
Bougria, M.,
and Machado, A.
(1996)
J. Biol. Chem.
271,
23105-23110[Abstract/Free Full Text]
|
| 26.
|
Robertson, N. M.,
Schulman, G.,
Karnik, S.,
Alnemri, E.,
and Litwack, G.
(1993)
Mol. Endocrinol.
7,
1226-1239[Abstract/Free Full Text]
|
| 27.
|
Burton, G.,
Galigniana, M. D.,
deLavallaz, S.,
Brachet-Cota, A.,
Sproviero, E.,
Ghini, A.,
and Lantos, C. P.
(1995)
Mol. Pharmacol.
47,
535-543[Abstract]
|
| 28.
|
Galigniana, M. D.,
Vicent, G. P.,
Piwien-Pilipuk, G.,
Burton, G.,
and Lantos, C. P.
(2000)
Mol. Pharmacol.
58,
58-70[Abstract/Free Full Text]
|
| 29.
|
Galicka, A.,
Sredzinska, K.,
and Gindzienski, A.
(2000)
Biochem. Biophys. Res. Commun.
269,
553-556[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Ryazanov, A. G.,
and Davydova, E. K.
(1989)
FEBS Lett.
251,
187-190[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Davydova, E.,
Malinin, N. L.,
and Ovchinnikov, L. P.
(1993)
Eur. J. Biochem.
215,
291-296[Medline]
[Order article via Infotrieve]
|
| 32.
|
Lenz, A.-G.,
Costabel, U.,
Shaltiel, S.,
and Levine, R. L.
(1989)
Anal. Biochem.
177,
419-425[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Esterbauer, H.,
and Cheeseman, K. H.
(1990)
Methods Enzymol.
186,
407-413[Medline]
[Order article via Infotrieve]
|
| 34.
|
Parrado, J.,
Bougria, M.,
Ayala, A.,
Castaño, A.,
and Machado, A.
(1999)
Free Radic. Biol. Med.
26,
362-370[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Tamarit, J.,
Cabiscol, E.,
and Ros, J.
(1997)
J. Biol. Chem.
271,
3027-3032
|
| 36.
|
Taffe, B. G.,
Takahashi, N.,
Kensler, T. W.,
and Manson, R. P.
(1987)
J. Biol. Chem.
262,
12143-12149[Abstract/Free Full Text]
|
| 37.
|
Quian, M. Q.,
Tang, P. L.,
and Morgan, E. H.
(1996)
Biochim. Biophys. Acta
1310,
293-302[Medline]
[Order article via Infotrieve]
|
| 38.
|
Henshaw, E. C.,
Guiney, D. G.,
and Hirsch, C. A.
(1973)
J. Biol. Chem.
248,
4367-4376[Abstract/Free Full Text]
|
| 39.
|
Howard, G. A.,
Adamson, S. D.,
and Herbert, E.
(1970)
J. Biol. Chem.
245,
6237-6239[Abstract/Free Full Text]
|
| 40.
|
Kabat, D.,
and Rich, A.
(1969)
Biochemistry
8,
3743-3749
|
| 41.
|
Hoer, W.,
and McCarty, K. S.
(1969)
Proc. Natl. Acad. Sci. U. S. A.
63,
1206-1213[Abstract/Free Full Text]
|
| 42.
|
Falvey, A. K.,
and Staehelin, T.
(1970)
J. Mol. Biol.
53,
21-34[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Smulson, M. E.,
and Rideau, C.
(1970)
J. Biol. Chem.
245,
5350-5360[Abstract/Free Full Text]
|
| 44.
|
Weissbach, H.,
and Ochoa, S.
(1976)
Annu. Rev. Biochem.
45,
191-216[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Riis, B.,
Rattan, S. I. S.,
Cavallius, J.,
and Clark, B. F. C.
(1989)
Biochem. Biophys. Res. Commun.
159,
1141-1146[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Ayuso-Parrilla, M. S.,
Martín-Requero, A.,
Pérez-Díaz, J.,
and Parrilla, R.
(1976)
J. Biol. Chem.
251,
7785-7790[Abstract/Free Full Text]
|
| 47.
|
Scornik, O. A.
(1974)
J. Biol. Chem.
249,
3876-3883[Abstract/Free Full Text]
|
| 48.
|
Meister, A.
(1991)
Pharmacol. Ther.
51,
155-194[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Lo, Y. Y. C.,
Wong, J. M. S.,
and Cruz, T. F.
(1996)
J. Biol. Chem.
271,
15073-15707
|
| 50.
|
Bae, G.-U.,
Seo, D.-W.,
Kwon, H. K.,
Lee, H. Y.,
Hong, S.,
Lee, Z. W., Ha, K. S.,
and Han, J. W.
(1999)
J. Biol. Chem.
274,
32596-32602[Abstract/Free Full Text]
|
| 51.
|
Shaw, M.,
Cohen, P.,
and Alessi, D. R.
(1998)
Biochem. J.
336,
241-246[Medline]
[Order article via Infotrieve]
|
| 52.
|
Prèville, X.,
Salvemini, F.,
Giraud, S.,
Chaufour, S.,
Paul, C.,
Stepien, G.,
Ursini, M. V.,
and Arrigo, A. P.
(1999)
Exp. Cell Res.
247,
61-78[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Prassad, N.,
Topping, R. S.,
Zhou, D.,
and Decker, S. J.
(2000)
Biochemistry
39,
6929-6935[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Kobayashi, T.,
and Cohen, P.
(1999)
Biochem. J.
339,
319-328[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Bhargava, A.,
Fullerton, M. J.,
Myles, K.,
Purdy, T. M.,
Funder, J. W.,
Pearce, D.,
and Cole, T.
(2001)
Endocrinology
142,
1587-1594[Abstract/Free Full Text]
|
| 56.
|
Pearce, D.
(2001)
Trends Endocrinol. Metab.
12,
341-347[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Verbeke, P.,
Fonager, J.,
Clark, B. F. C.,
and Rattan, S. I.
(2001)
Cell Biol. Int.
25,
845-857[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|